文献速递临床试验与 GCP流行病学与生物统计

REACH-ASD:一项英国随机对照试验,评估针对新诊断自闭症谱系障碍儿童照护者的诊断后心理教育与接纳承诺疗法项目对比常规治疗对心理健康与适应的影响

REACH-ASD: a UK randomised controlled trial of a new post-diagnostic psycho-education and acceptance and commitment therapy programme against treatment-as-usual for improving the mental health and adjustment of caregivers of children recently diagnosed with autism spectrum disorder.
PubMed 文献 · Trials · 2022-07-22

本研究为多中心、两组、单盲随机对照试验,纳入380名近期诊断为自闭症谱系障碍的2-15岁儿童的照护者,按2:1随机分配至Empower-Autism项目联合常规治疗组或当地常规诊断后支持联合常规治疗组,主要结局为52周时照护者心理健康(General Health Questionnaire-30)。

要点

  • Empower-Autism为基于接纳承诺疗法的团体手册化诊断后干预,联合常规治疗对比当地常规诊断后支持联合常规治疗。
  • 主要结局为52周随访时照护者心理健康(General Health Questionnaire-30),采用意向性分析。
  • 将进行成本效果可接受性分析及决策模型外推至更长时间。

核心结论

  • 该试验旨在检验Empower-Autism项目对比当地常规诊断后支持在改善照护者心理健康与适应方面的临床与成本效果。
  • 若有效,该新方法将填补自闭症儿童及其家庭循证照护路径的关键缺口。

研究设计与样本

  • 多中心、两组平行、单盲(研究者盲)随机对照试验。
  • 招募来自英格兰西北部NHS或地方当局中心的近期诊断为自闭症谱系障碍的2-15岁儿童的照护者。
  • 按儿童个体随机,每名儿童一名索引照护者,按中心分层,2:1随机比例分配至Empower-Autism联合常规治疗组或当地常规诊断后支持联合常规治疗组。
  • 样本量N=380(约253例干预组/127例常规治疗组)。

主要发现

  • 主要结局为52周随访时照护者心理健康(General Health Questionnaire-30)。
  • 次要结局包括12、26、52周随访时照护者关键指标(幸福感、自我效能、适应、自闭症知识)及52周终点时家庭与儿童结局(幸福感与功能)。
  • 主要分析将遵循意向性治疗原则,使用线性混合模型,随机截距包括组别与重复测量。
  • 成本效果可接受性分析覆盖52周,并进行决策模型外推至更长时间。

关键数值与推荐

  • Empower-Autism为团体、手册化、诊断后项目,结合自闭症心理教育与基于接纳承诺疗法的心理治疗成分,以支持照护者心理健康、压力管理及对儿童诊断的适应。
  • 对照为任何当地常规团体诊断后心理教育支持。
  • 服务接受情况将通过卫生经济数据明确。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autism is a neurodevelopmental disability affecting over 1% of UK children. The period following a child's autism diagnosis can present real challenges in adaptation for families. Twenty to 50% of caregivers show clinically significant levels of mental health need within the post-diagnostic period and on an ongoing basis. Best practice guidelines recommend timely post-diagnostic family support. Current provision is patchy, largely unevidenced, and a source of dissatisfaction for both families and professionals. There is a pressing need for an evidenced programme of post-diagnostic support focusing on caregiver mental health and adjustment, alongside autism psycho-education. This trial tests the clinical and cost-effectiveness of a new brief manualised psychosocial intervention designed to address this gap. METHODS: This is a multi-centre two-parallel-group single (researcher)-blinded randomised controlled trial of the Empower-Autism programme plus treatment-as-usual versus usual local post-diagnostic offer plus treatment-as-usual. Caregivers of children aged 2-15 years with a recent autism diagnosis will be recruited from North West England NHS or local authority centres. Randomisation is individually by child, with one "index" caregiver per child, stratified by centre, using 2:1 randomisation ratio to assist recruitment and timely intervention. Empower-Autism is a group-based, manualised, post-diagnostic programme that combines autism psycho-education and psychotherapeutic components based on Acceptance and Commitment Therapy to support caregiver mental health, stress management and adjustment to their child's diagnosis. The comparator is any usual local group-based post-diagnostic psycho-education offer. Receipt of services will be specified through health economic data. PRIMARY OUTCOME: caregiver mental health (General Health Questionnaire-30) at 52-week follow-up. SECONDARY OUTCOMES: key caregiver measures (wellbeing, self-efficacy, adjustment, autism knowledge) at 12-, 26- and 52-week follow-up and family and child outcomes (wellbeing and functioning) at 52-week endpoint. SAMPLE: N=380 (approximately 253 intervention/127 treatment-as-usual). Primary analysis will follow intention-to-treat principles using linear mixed models with random intercepts for group membership and repeated measures. Cost-effectiveness acceptability analyses will be over 52 weeks, with decision modelling to extrapolate to longer time periods. DISCUSSION: If effective, this new approach will fill a key gap in the provision of evidence-based care pathways for autistic children and their families. TRIAL REGISTRATION: ISRCTN 45412843 . Prospectively registered on 11 September 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Leadbitter K, Smallman R, James K, et al. REACH-ASD: a UK randomised controlled trial of a new post-diagnostic psycho-education and acceptance and commitment therapy programme against treatment-as-usual for improving the mental health and adjustment of caregivers of children recently diagnosed with autism spectrum disorder. Trials. 2022. PMID: 35869533. doi:10.1186/s13063-022-06524-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。